METHOD AND REAGENT FOR INHIBITING EXPRESSION OF DISEASE RELATED GENES

PROBLEM TO BE SOLVED: To provide a reagent useful as an inhibitor for expression of genes relating to diseases such as inflammation, autoimmune disease, clonic myelogenic leukemia, airways disease or the like and a method for purifying an RNA. SOLUTION: Disclosed is a method for purifying a chemical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MATULIC-ADAMIC JASENKA, MODAK ANIL, USMAN NASSIM, DRAPER KENNETH G, THOMPSON JAMES D, DIRENZO ANTHONY, DUDYCZ LECH W, CHOWRIRA BHARAT, SWEEDLER DAVID, MCSWIGGEN JAMES A, WINCOTT FRANCINE E, KISICH KEVIN, STINCHCOMB DAN T, BEIGELMAN LEONID, GRIMM SUSAN, KARPEISKY ALEXANDER, SULLIVAN SEAN M, TRACZ DANUTA, PAVCO PAMELA, WOOLF TOD
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DERIVATIVES THEREOF ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS SUGARS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PROBLEM TO BE SOLVED: To provide a reagent useful as an inhibitor for expression of genes relating to diseases such as inflammation, autoimmune disease, clonic myelogenic leukemia, airways disease or the like and a method for purifying an RNA. SOLUTION: Disclosed is a method for purifying a chemically synthesized RNA having one or more chemical modifications, wherein the method comprises (a) loading the RNA into a reversed phase high performance liquid chromatography (HPLC) column, wherein the RNA includes a 5'-protective group, (b) eluting the RNA by passing an appropriate buffer solution into the reversed phase column, (c) eliminating the 5'-protective group from the RNA, (d) loading the deprotected RNA into an anion exchange HPLC column, (e) eluting the RNA by passing an appropriate buffer solution into the anion exchange column, and (f) collecting the eluate from the anion exchange column and collecting the RNA from the eluate under the condition capable of purifying the RNA. COPYRIGHT: (C)2005,JPO&NCIPI